The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors
Abstract
Conspectus The common existence of hypoxia in solid tumors has been heavily researched because it renders tumors more resistant to most standard therapeutic methods, such as radiotherapy (RT), chemotherapy, and photodynamic therapy (PDT), and is associated with a more malignant phenotype and poor survival in patients with tumors. The development of hypoxia modulation methods for advanced therapeutic activity is therefore of great interest but remains a considerable challenge. Since the significant development of nanotechnology and nanomedicine, functionalized nanomaterials can be exploited as adjuvant “drugs” for these oxygen-dependent standard therapies or as hypoxia initiators for advanced new therapies to solid tumors. In this Account, we summarize our recent studies on the design and synthesis of nanomaterials with a set of desired chemistry benefits achievable by modulating hypoxia, suggesting a valid therapeutic option for tumors. The investigated strategies can be categorized into three groups: The first strategy is based on countering hypoxia. Considering that O 2 deficiency is the major obstacle for the oxygen-dependent therapies, we initially developed methods to supply O 2 by taking advantage of the hypoxia-responsive properties of nano-MnO 2 or nanomaterials’ photothermal effects for increased intratumoral blood flow. The second approach is to disregard hypoxia. Possible benefits of nanoagents include reducing/eliminating reliance on O 2 or making O 2 replacements as adjuvants to standard therapies. To this end, we investigated a nano-upconversion/scintillator with the capacity toup-/down-convert near-infrared light (NIR)/X-ray to luminescence in the ultraviolet/visible region fortype-I PDT with minimized oxygen-tension dependency or developed Fe-based nanomaterials for chemodynamic therapy (CDT) without external energy and oxygen participation for efficient free radical killing of deep tumors. The third strategy involves exploiting hypoxia. The unique biological characteristics of hypoxia are exploited to activate nanoagents for new therapies. To address the discrepancy between the nanoagents’ demand and supply within the hypoxia region, a smart “molecule–nano” medicine that stays small-molecule-like in the bloodstream and turns into self-assembled nanovesicles after entry into the hypoxia region was constructed for hypoxia-adaptive photothermal therapy (PTT). In addition to traditional anti-angiogenesis therapy, we prepared Mg 2 Si nanoparticles by a special self-propagating high-temperature synthesis approach. These nanoparticles can directly remove the intratumoral oxygen via the oxidation reactions of Mg 2 Si and later efficiently block the rapid reoxygenation via tumor blood vessels by the resultant SiO 2 microsheets for cancer starvation therapy. Taken together, these findings indicate that nanomaterials will assume a valuable role for anticancer exploration based on either their properties to make up oxygen deficiency or the use of hypoxia for therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Yang, G., Xu, L., Chao, Y., Xu, J., Sun, X., Wu, Y., Peng, R., & Liu, Z. (2017) · Nature Communications · doi:10.1038/s41467-017-01050-0 · Cited by 1,477
Zhang, C., Bu, W., Ni, D., Zhang, S., Li, Q., Yao, Z., Zhang, J., Yao, H., Wang, Z., & Shi, J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201510031 · Cited by 1,269
Self-citationCheng, Y., Cheng, H., Jiang, C., Qiu, X., Wang, K., Huan, W., Yuan, A., Wu, J., & Hu, Y. (2015) · Nature Communications · doi:10.1038/ncomms9785 · Cited by 941
Li, S.-Y., Cheng, H., Xie, B.-R., Qiu, W.-X., Zeng, J.-Y., Li, C.-X., Wan, S.-S., Zhang, L., Liu, W.-L., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b02533 · Cited by 780
Photodynamic therapy of cancer. Basic principles and applications
Juarranz, Á., Jaén, P., Sanz-Rodríguez, F., Cuevas, J., & González, S. (2008) · Clinical and Translational Oncology · doi:10.1007/s12094-008-0172-2 · Cited by 762
Fan, W., Bu, W., Shen, B., He, Q., Cui, Z., Liu, Y., Zheng, X., Zhao, K., & Shi, J. (2015) · Advanced Materials · doi:10.1002/adma.201405141 · Cited by 665
Self-citationZhu, W., Dong, Z., Fu, T., Liu, J., Chen, Q., Li, Y., Zhu, R., Xu, L., & Liu, Z. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201600676 · Cited by 588
Cited by
Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
Mi, P. (2020) · Theranostics · doi:10.7150/thno.38069 · Cited by 830
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Self-citationConquering the Hypoxia Limitation for Photodynamic Therapy
Wan, Y., Fu, L., Li, C., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202103978 · Cited by 705
Nguyen, V.-N., Yan, Y., Zhao, J., & Yoon, J. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00606 · Cited by 650
Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy
Liang, S., Deng, X., Ma, P., Cheng, Z., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202003214 · Cited by 598
Zhang, C., Yan, K., Fu, C., Peng, H., Hawker, C. J., & Whittaker, A. K. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00632 · Cited by 493
Liu, Y., Zhen, W., Wang, Y., Liu, J., Jin, L., Zhang, T., Zhang, S., Zhao, Y., Song, S., Li, C., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201813702 · Cited by 374
Self-citationPhotodynamic therapy for hypoxic tumors: Advances and perspectives
Huang, L., Zhao, S., Wu, J., Yu, L., Singh, N., Yang, K., Lan, M., Wang, P., & Kim, J. S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213888 · Cited by 366
Type I photodynamic therapy by organic–inorganic hybrid materials: From strategies to applications
Wang, Y.-Y., Liu, Y.-C., Sun, H., & Guo, D.-S. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.05.016 · Cited by 344
Self-citationZeng, S., Liu, X., Kafuti, Y. S., Kim, H., Wang, J., Peng, X., Li, H., & Yoon, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00799a · Cited by 341
Wang, M., Chang, M., Chen, Q., Wang, D., Li, C., Hou, Z., Lin, J., Jin, D., & Xing, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120093 · Cited by 322
Recent Advances in Glucose‐Oxidase‐Based Nanocomposites for Tumor Therapy
Wang, M., Wang, D., Chen, Q., Li, C., Li, Z., & Lin, J. (2019) · Small · doi:10.1002/smll.201903895 · Cited by 302
Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy
Fu, S., Li, G., Zang, W., Zhou, X., Shi, K., & Zhai, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.012 · Cited by 266
Stimuli responsive nanosonosensitizers for sonodynamic therapy
Jiang, Z., Xiao, W., & Fu, Q. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.003 · Cited by 173
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Tongue cancer tailored photosensitizers for NIR-II fluorescence imaging guided precise treatment
Yin, B., Qin, Q., Li, Z., Wang, Y., Liu, X., Liu, Y., Huan, S., Zhang, X., & Song, G. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101550 · Cited by 65
Self-citation
Metadata
- Authors
- Liu, Y., Jiang, Y., Zhang, M., Tang, Z., He, M., & Bu, W.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-09-20
- Volume
- 51
- Issue
- 10
- Pages
- 2502-2511
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W2890715270
- Cited by
- 307
- References
- 36
- FWCI
- 13.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.